# Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

> **NCT02254018** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 31 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** bivatuzumab mertansine

## Key facts

- **NCT ID:** NCT02254018
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09-01
- **Primary completion:** 2005-02-01
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254018, "Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02254018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*